NYSE:DGX - Quest Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$87.81 +2.31 (+2.70 %)
(As of 02/17/2019 04:00 PM ET)
Previous Close$87.81
Today's Range$85.2101 - $88.05
52-Week Range$78.95 - $116.49
Volume2.10 million shs
Average Volume1.30 million shs
Market Capitalization$11.95 billion
P/E Ratio16.26
Dividend Yield2.48%
Beta0.89
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.71 billion
Cash Flow$7.2212 per share
Book Value$36.35 per share

Profitability

Net Income$772 million

Miscellaneous

Employees45,000
Market Cap$11.95 billion
OptionableOptionable

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Thursday, November 29th. Stockholders of record on Tuesday, January 15th will be paid a dividend of $0.53 per share on Wednesday, January 30th. This represents a $2.12 annualized dividend and a dividend yield of 2.41%. The ex-dividend date of this dividend is Monday, January 14th. This is a positive change from Quest Diagnostics's previous quarterly dividend of $0.50. View Quest Diagnostics' Dividend History.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its Board of Directors has initiated a stock buyback program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 7.8% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board of directors believes its shares are undervalued.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) released its quarterly earnings data on Thursday, February, 14th. The medical research company reported $1.36 EPS for the quarter, missing analysts' consensus estimates of $1.37 by $0.01. The medical research company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.88 billion. Quest Diagnostics had a return on equity of 15.71% and a net margin of 11.30%. The company's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.40 earnings per share. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, April 18th 2019. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY 2019 earnings guidance on Thursday, February, 14th. The company provided EPS guidance of $6.40 for the period, compared to the Thomson Reuters consensus estimate of $6.56. The company issued revenue guidance of $7.6-7.75 billion, compared to the consensus revenue estimate of $7.76 billion.

What price target have analysts set for DGX?

18 equities research analysts have issued 12-month target prices for Quest Diagnostics' shares. Their predictions range from $90.00 to $121.00. On average, they anticipate Quest Diagnostics' share price to reach $103.4375 in the next twelve months. This suggests a possible upside of 17.8% from the stock's current price. View Analyst Price Targets for Quest Diagnostics.

What is the consensus analysts' recommendation for Quest Diagnostics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Quest Diagnostics.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. Barclays PLC analysts commented, "We were surprised there was another leg down in the quarter, though one silver lining is that volume growth of 3.4% appears improved – and the company noted that 2019 is off to a good start. $1.36 was modestly better than our forecast of $1.35. Additionally, Quest had an active 4Q18 of capital deployment, repurchasing $175mm of stock, $200mm towards acquisitions, and $68mm toward dividends. Ultimately, shares now trade at 13x our new 2019 EPS forecast of $6.40, and we believe sentiment is near a trough despite the potential for leverageable share gains in 2019. In our view, structural trends should be at the back of the national labs to consolidate testing share – and this is Quest’s time to shine." (2/15/2019)
  • 2. According to Zacks Investment Research, "Quest Diagnostics has underperformed its industry in the past year. After a disappointing third quarter performance, we are concerned about factors like unfavorable changes in prescription drug monitoring, vitamin D testing and hepatitis C testing marketplace that can dent growth going forward. Also, in the last-reported quarter, a rise in patient concession impacted the top line, resulting in a decline in revenue per requisition. Tough competition and reimbursement issues are other concerns. On a brighter note, Quest Diagnostics is currently refocusing on diagnostic information services business and disciplined capital deployment. The company’s’ acquisitions and collaborations with hospitals and integrated delivery networks (the latest being Provant Health) continue to act as major growth drivers. We are upbeat about the company entering into a strategic partnership agreement with UnitedHealthcare." (2/12/2019)
  • 3. Canaccord Genuity analysts commented, "We stick with our BUY rating, and lower our PT from $105 to $98, based on 14.3x our 2020 adj. EPS estimate." (11/30/2018)

Has Quest Diagnostics been receiving favorable news coverage?

News stories about DGX stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Quest Diagnostics earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.

Who are some of Quest Diagnostics' key competitors?

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.56%), Macquarie Group Ltd. (5.67%), Victory Capital Management Inc. (2.07%), Geode Capital Management LLC (1.58%), Dimensional Fund Advisors LP (1.46%) and Northern Trust Corp (1.45%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jenne K Britell, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which major investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., BlackRock Inc., Robeco Institutional Asset Management B.V., Squarepoint Ops LLC, Westfield Capital Management Co. LP, Lord Abbett & CO. LLC, Bank of Montreal Can and Bank of New York Mellon Corp. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Robert A Klug and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which major investors are buying Quest Diagnostics stock?

DGX stock was acquired by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Macquarie Group Ltd., Two Sigma Advisers LP, Two Sigma Investments LP, First Trust Advisors LP, State of Tennessee Treasury Department, Geode Capital Management LLC and State Treasurer State of Michigan. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $87.81.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $11.95 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is http://www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  681 (Vote Underperform)
Total Votes:  1,056
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Featured Article: What is a put option?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel